QDEL
QuidelOrtho Corporation
Healthcare · Medical - Instruments & Supplies
Deeply Undervalued·Quality 60·RSI 43·DCF -356%·Conviction 75
Investment Thesis — QuidelOrtho Corporation
The market overreacts to QuidelOrtho's post-COVID revenue normalization, extrapolating recent declines as structural rather than cyclical. Investors miss that the core diagnostics business is stabilizing, and cost actions set a floor for margins ahead of any volume recovery.
Catalysts
- Evidence of core diagnostics revenue stabilization
- Announcement of successful new product launches
- Material improvement in operating margins from cost actions
Risk Factors
- Prolonged hospital budget constraints impacting test volumes
- Accelerating competition from larger diagnostics players
- Execution missteps in cost restructuring or product launches
Key Debates
Base Business Growth Exceeds 3% by Q3, Re-rating Fwd P/E
QDEL Price Rises 25% by Q4 from Short Squeeze
Synergies Boost EPS 15% by Q4, Re-rating P/E